BR112015013540A8 - formulação em solução de anticorpo hum13b8-b de interleucina-23 p19 anti-humano (il-23p19), e, uso de uma formulação em solução - Google Patents

formulação em solução de anticorpo hum13b8-b de interleucina-23 p19 anti-humano (il-23p19), e, uso de uma formulação em solução Download PDF

Info

Publication number
BR112015013540A8
BR112015013540A8 BR112015013540A BR112015013540A BR112015013540A8 BR 112015013540 A8 BR112015013540 A8 BR 112015013540A8 BR 112015013540 A BR112015013540 A BR 112015013540A BR 112015013540 A BR112015013540 A BR 112015013540A BR 112015013540 A8 BR112015013540 A8 BR 112015013540A8
Authority
BR
Brazil
Prior art keywords
solution formulation
human
hum13b8
humlebin
antibody
Prior art date
Application number
BR112015013540A
Other languages
English (en)
Other versions
BR112015013540B1 (pt
BR112015013540A2 (pt
Inventor
Badkar Aniket
S Kashi Ramesh
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934859&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015013540(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of BR112015013540A2 publication Critical patent/BR112015013540A2/pt
Publication of BR112015013540A8 publication Critical patent/BR112015013540A8/pt
Publication of BR112015013540B1 publication Critical patent/BR112015013540B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

1 / 1 resumo “formulaã‡ãƒo em soluã‡ãƒo, mã‰todos para tratar uma doenã‡a autoimune, doenã‡a inflamatã“ria ou distãšrbio proliferativo e psorãase, e, uso de uma formulaã‡ãƒo em soluã‡ãƒo” a presente invenã§ã£o fornece formulaã§ãµes em soluã§ã£o de alta concentraã§ã£o de anticorpo hum13b8-b de interleucina-23 p19 anti-humano (il-23p19), e seu uso no tratamento de vã¡rios distãºrbios.
BR112015013540-4A 2012-12-13 2013-12-09 Formulação em solução estável de anticorpo hum13b8-b de interleucina-23 p19 anti- humano (il-23p19), e, uso de uma formulação em solução BR112015013540B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737035P 2012-12-13 2012-12-13
US61/737,035 2012-12-13
PCT/US2013/073825 WO2014093203A1 (en) 2012-12-13 2013-12-09 SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES

Publications (3)

Publication Number Publication Date
BR112015013540A2 BR112015013540A2 (pt) 2017-11-14
BR112015013540A8 true BR112015013540A8 (pt) 2018-04-17
BR112015013540B1 BR112015013540B1 (pt) 2021-04-27

Family

ID=50934859

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015013540-4A BR112015013540B1 (pt) 2012-12-13 2013-12-09 Formulação em solução estável de anticorpo hum13b8-b de interleucina-23 p19 anti- humano (il-23p19), e, uso de uma formulação em solução

Country Status (31)

Country Link
US (3) US20150329632A1 (pt)
EP (1) EP2931313B1 (pt)
JP (1) JP6266012B2 (pt)
KR (1) KR102004585B1 (pt)
CN (1) CN104870016B (pt)
AU (1) AU2013359767B2 (pt)
BR (1) BR112015013540B1 (pt)
CA (1) CA2894869C (pt)
CL (1) CL2015001608A1 (pt)
CY (1) CY1121895T1 (pt)
DK (1) DK2931313T3 (pt)
EA (1) EA034616B1 (pt)
ES (1) ES2732861T3 (pt)
HK (1) HK1215194A1 (pt)
HR (1) HRP20191137T1 (pt)
HU (1) HUE045668T2 (pt)
IL (3) IL307581A (pt)
LT (1) LT2931313T (pt)
MX (1) MX357936B (pt)
MY (1) MY187921A (pt)
NZ (1) NZ708443A (pt)
PE (1) PE20151524A1 (pt)
PH (1) PH12015501296A1 (pt)
PL (1) PL2931313T3 (pt)
PT (1) PT2931313T (pt)
RS (1) RS59057B1 (pt)
SI (1) SI2931313T1 (pt)
TR (1) TR201909584T4 (pt)
UA (1) UA117466C2 (pt)
WO (1) WO2014093203A1 (pt)
ZA (1) ZA201504408B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI761959B (zh) * 2014-11-07 2022-04-21 瑞士商諾華公司 治療眼部疾病之方法
KR20190129061A (ko) * 2017-03-31 2019-11-19 메이지 세이카 파루마 가부시키가이샤 수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법
KR20200129125A (ko) * 2018-03-05 2020-11-17 얀센 바이오테크 인코포레이티드 항-il23 특이적 항체로 크론병을 치료하는 방법
JP2022532965A (ja) * 2018-11-21 2022-07-21 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度タンパク質製剤
WO2020172002A1 (en) 2019-02-18 2020-08-27 Eli Lilly And Company Therapeutic antibody formulation
AU2020226619A1 (en) * 2019-02-20 2021-08-05 Amgen Inc. Methods of determining protein stability
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
TW202123965A (zh) * 2019-09-09 2021-07-01 德商百靈佳殷格翰國際股份有限公司 抗-il-23p19抗體調配物
WO2021126435A1 (en) * 2019-12-20 2021-06-24 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 p19 antibodies and methods of use thereof
BR112022022919A2 (pt) * 2020-05-13 2022-12-20 Innovent Biologics Suzhou Co Ltd Formulação compreendendo o anticorpo anti-il-23p19, método para preparar o mesmo e uso do mesmo".

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366706A1 (en) 1999-03-11 2000-09-14 Schering Corporation Mammalian cytokines; related reagents and methods
IL148300A0 (en) 1999-09-09 2002-09-12 Schering Corp Mammalian cytokines; related reagents and methods
ES2338218T3 (es) 2001-07-25 2010-05-05 Facet Biotech Corporation Formulacion farmacologica liofilizada estable de anticuerpos igg daclizumab.
JP5290489B2 (ja) * 2001-11-08 2013-09-18 アッヴィ・バイオセラピューティクス・インコーポレイテッド Ｉｇｇ抗体の安定な液体医薬製剤
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040219150A1 (en) 2003-02-06 2004-11-04 Cua Daniel J. Uses of mammalian cytokine; related reagents
PT3417875T (pt) 2003-02-10 2020-08-24 Biogen Ma Inc Formulação de imunoglobulinas e método de preparação das mesmas
PL1601694T3 (pl) 2003-03-10 2010-02-26 Merck Sharp & Dohme Zastosowania antagonistów IL-23; pokrewne reagenty
RU2332986C2 (ru) * 2003-04-04 2008-09-10 Дженентек, Инк. Высококонцентрированные композиции антител и белков
ATE533502T1 (de) 2004-02-17 2011-12-15 Schering Corp Verfahren zur modulation der il-23-aktivität; relevante reagenzien
JP4879884B2 (ja) 2004-04-12 2012-02-22 メディミューン，エルエルシー 抗−ｉｌ−９抗体製剤及びその使用法
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
HUE042561T2 (hu) 2005-06-30 2019-07-29 Janssen Biotech Inc Anti-IL-23-ellenanyagok, készítmények, eljárások és alkalmazások
US7872102B2 (en) 2005-08-25 2011-01-18 Eli Lilly And Company Anti-IL-23 antibodies
PL1931710T3 (pl) 2005-08-31 2017-06-30 Merck Sharp & Dohme Corp. Przeciwciała anty-il-23 skonstruowane techniką inżynierii genetycznej
RS53685B1 (en) 2005-12-29 2015-04-30 Janssen Biotech Inc. HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, METHODS AND APPLICATIONS
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
US7705132B2 (en) 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
US20090060906A1 (en) 2007-01-09 2009-03-05 Wyeth Anti-IL-13 antibody formulations and uses thereof
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
MX2009009079A (es) * 2007-02-23 2009-08-31 Schering Corp Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) 2007-02-23 2009-11-02 Schering Corp Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009114040A2 (en) 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
MY171841A (en) 2007-12-21 2019-11-04 Hoffmann La Roche Antibody formulation
EP2297209A4 (en) * 2008-06-03 2012-08-01 Abbott Lab IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF
CA2734919C (en) * 2008-08-27 2016-08-16 Schering Corporation Lyophilized formulations of engineered anti-il-23p19 antibodies
JP5642683B2 (ja) * 2008-09-19 2014-12-17 ファイザー・インク 安定な液体抗体配合物
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
AU2010338305A1 (en) * 2009-12-29 2012-05-24 F. Hoffmann-La Roche Ag Antibody formulation
LT2691112T (lt) 2011-03-31 2018-07-25 Merck Sharp & Dohme Corp. Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
EP2822591B1 (en) * 2012-03-07 2018-05-02 Cadila Healthcare Limited Pharmaceutical formulations of tnf-alpha antibodies

Also Published As

Publication number Publication date
PL2931313T3 (pl) 2019-10-31
EA201591133A1 (ru) 2015-10-30
IL278295A (pt) 2020-12-31
JP2016505572A (ja) 2016-02-25
CY1121895T1 (el) 2020-10-14
DK2931313T3 (da) 2019-07-15
WO2014093203A1 (en) 2014-06-19
EA034616B1 (ru) 2020-02-27
IL278295B1 (en) 2023-11-01
KR102004585B1 (ko) 2019-07-26
PH12015501296B1 (en) 2015-08-24
PH12015501296A1 (en) 2015-08-24
RS59057B1 (sr) 2019-08-30
EP2931313A1 (en) 2015-10-21
BR112015013540B1 (pt) 2021-04-27
ZA201504408B (en) 2017-09-27
CA2894869A1 (en) 2014-06-19
MX2015007213A (es) 2016-08-03
IL239150A0 (en) 2015-07-30
IL278295B2 (en) 2024-03-01
IL307581A (en) 2023-12-01
IL239150B (en) 2020-11-30
TR201909584T4 (tr) 2019-07-22
US20210188964A1 (en) 2021-06-24
SI2931313T1 (sl) 2019-09-30
AU2013359767B2 (en) 2018-04-05
AU2013359767A1 (en) 2015-07-23
MX357936B (es) 2018-07-31
CL2015001608A1 (es) 2015-10-30
EP2931313B1 (en) 2019-05-08
PE20151524A1 (es) 2015-11-06
JP6266012B2 (ja) 2018-01-24
EP2931313A4 (en) 2016-08-03
CN104870016B (zh) 2018-05-08
UA117466C2 (uk) 2018-08-10
US20240239884A1 (en) 2024-07-18
HK1215194A1 (zh) 2016-08-19
CA2894869C (en) 2021-06-15
HRP20191137T1 (hr) 2019-09-20
CN104870016A (zh) 2015-08-26
ES2732861T3 (es) 2019-11-26
BR112015013540A2 (pt) 2017-11-14
LT2931313T (lt) 2019-09-25
HUE045668T2 (hu) 2020-01-28
MY187921A (en) 2021-10-28
KR20150092763A (ko) 2015-08-13
NZ708443A (en) 2018-05-25
PT2931313T (pt) 2019-07-10
US20150329632A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
BR112015013540A8 (pt) formulação em solução de anticorpo hum13b8-b de interleucina-23 p19 anti-humano (il-23p19), e, uso de uma formulação em solução
CL2017002110A1 (es) Nuevos conjugados de anticuerpos y usos de los mismos (divisional solicitud 201502357)
CY1119576T1 (el) Ν-ακυλ-(3-υποκατεστημενες)-(8-υποκατεστημενες)-5,6-διϋδρο-[1,2,4]τριαζολο[4,3-α]πυραζινες ως επιλεκτικοι ανταγωνιστες του υποδοχεα νκ-3, φαρμακευτικη συνθεση, μεθοδοι για χρηση σε διαμεσολαβουμενες απο τον υποδοχεα νκ-3 διαταραχες
DOP2016000109A (es) Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas.
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
DOP2015000246A (es) Derivados de oxopiridina sustituida y usos de los mismos en el tratamiento de trastornos cardiovasculares
CL2015002724A1 (es) Métodos para tratar la enfermedad de crohn utilizando un anticuerpo anti-il23
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
UY35350A (es) Pirimidinas condensadas sustituidas con trifluorometilo y su uso
BR112016010422A8 (pt) suplemento dietético, e uso de uma composição
CL2015001941A1 (es) Los anticuerpos anti-il-17a y su uso en el tratamiento de trastornos autoinmunes e inflamatorias.
CL2011001361A1 (es) Compuestos derivados de n-(imidazo[1,2-a]pirazin-8-il)-1h-amina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades mediadas por inhiibicion de actividad syk, tales como cancer, trastornos alergicos o inflamatorios.
BR112014020826A2 (pt) moduladores e métodos de uso
CL2015002501A1 (es) Compuestos y usos de estos para la modulación de la hemoglobina
WO2014159595A3 (en) Human antibodies to nav1.7
BR112015022934A8 (pt) esteróides neuroativos, composições e usos destes
BR112015021521A2 (pt) anticorpos anti-crth2 e métodos para seu uso
CL2008000935A1 (es) Anticuerpo monoclonal humano anti-ige o fragmento del mismo; acido nucleico que lo codifica; vector y celula huesped; metodo de preparacion; composicion farmaceutica que lo comprende; y su uso en el tratamiento de trastornos relacionados con ige.
BR112015030356A2 (pt) métodos de tratamento de uma taupatia
GT201600002A (es) Bencil-1h-pirazolo[3,4-b]piridinas y su uso
CO2019009586A2 (es) Anticuerpos anti-gitr y métodos de uso de los mismos
CL2013002811A1 (es) Anticuerpo monoclonal aislado que se une a un epitopo del inhibidor de la ruta del factor tisular humano; molecula de acido nucleico que lo codifica; composicion farmaceutica que lo comprende; y su uso para tratar deficiencias o defectos geneticos o adquiridos en la coagulacion.
CO7350653A2 (es) Retinoides y uso de los mismos
UY35654A (es) Dihidroquinoxalinonas y dihidropiridopirazinonas modificadas como inhibidores de la proteína bet
CY1118838T1 (el) Ηρν-100 για χρηση στην αντιμετωπιση διαταραχων κατακρατησης αζωτου

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08G Application fees: restoration [chapter 8.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 09/12/2013, OBSERVADAS AS CONDICOES LEGAIS.